Project
Keyvibe - MK7684A-010
Ongoing - recruitment closed · 2023 until 2099
Aeppli Stefanie, Sennhauser Andrina, Müller Fiona
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Ongoing - recruitment closed
Start Date
2023
End Date
2099
Financing
Industry
Labels
melanoma
Brief description/objective
A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE-010)